Key result
Statin use is linked to greater major cardiovascular events reduction in patients with highest polygenic risk.
Why the study?
Does statin use reduce major adverse cardiovascular events more effectively in primary prevention patients with high versus low coronary artery disease polygenic risk scores?
Cohort
Yes
Does statin use reduce major adverse cardiovascular events more effectively in primary prevention patients with high versus low coronary artery disease polygenic risk scores?
Answers are grounded in this paper and cite their sources.
Coronary artery disease polygenic risk scores that include sub-genome-wide variants can identify primary prevention patients who derive greater relative risk reduction from statin therapy.
Background Polygenic risk scores derived from coronary artery disease genome-wide association studies are associated with statin relative risk reduction. Objective Examine the relationship between coronary artery disease polygenic risk scores that include variants below thresholds of genome-wide significance and statin primary prevention of major adverse cardiovascular events. Methods We generated coronary artery disease polygenic risk scores for participants with no past evidence of myocardial infarction from three electronic health record-linked genetic biobanks: All of Us Research Program, Genetic Epidemiology Research on Adult Health and Aging, and the Million Veteran Program. We scored each participant using three different polygenic risk scores: two with both genome-wide and sub-genome-wide significant variants (metaGRS and PRS2022) and one with only variants meeting genome-wide significance (164SNP). We used covariate-adjusted Cox regression models to compare risk of major adverse cardiovascular events between statin users and nonusers matched on age, sex, smoking status, type 2 diabetes mellitus, and hypertension within strata defined by polygenic risk. For the primary analysis, we performed a meta-analysis across the three cohorts for the delta hazard ratio of statin effectiveness between high and low polygenic risk. Results Across all cohorts, statin use was more strongly associated with reduced risk of major adverse cardiovascular events among participants with no myocardial infarction at index in the highest versus lowest polygenic risk score group for the PRS2022 (interaction beta 0.19, standard error 0.07, interaction P =2.3E-3) and metaGRS (interaction beta 0.14, standard error 0.07, interaction P =.02) scores. However, the association was not statistically significant (interaction beta 0.09, standard error 0.07, interaction P =.08) for the 164SNP risk score. Conclusions We demonstrated that the association between coronary artery disease polygenic risk scores and statin relative risk reduction can by enhanced with the inclusion of sub-genome-wide variants, paving the way for more research to establish clinical utility.
No takes yet. Share an insight, caveat, or question.
Haldar et al. (2025) conducted a cohort in Primary prevention of major adverse cardiovascular events. Statin use vs. Statin nonusers was evaluated on Major adverse cardiovascular events (interaction beta 0.19, p=2.3E-3). Statin use was more strongly associated with reduced risk of major adverse cardiovascular events in the highest versus lowest polygenic risk score group.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: